Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).

University of Maryland School of Medicine, Baltimore

MUSC/Division Cardiology, Charleston

Emory University, Atlanta

University of Alabama at Birmingham, Birmingham

The Lindner Clinical Trial Center, Cincinnati

Brian LGH Heart Institute, Lincoln

University of Iowa Hospital and Clinics, Iowa City

Sanofi-aventis Administrative Office, Laval

Sanofi-aventis Administrative Office, Guildford Surrey